COVAXIN is being widely used in India for Covid-19 and it illicited good result so far. However, the vaccine was restricted for use only in India till today.
Now Covaxin is anticipated to get approval from the WHO by the end of the third or fourth quarter of 2021, Bharat Biotech’s Business Development and International Advocacy Head Dr. Raches Ella revealed. Currently, those on the WHO’s Emergency Use Listing comprise vaccines from leading pharma giants such as Moderna, Pfizer, AstraZeneca, Johnson and Johnson, and Sinopharm.
The emergency use approval can bring remarkable changes amid the COVID-19 crisis as it is likely to boost confidence in countries to import COVAXIN, allow its manufacturing globally and ease foreign travel for those vaccinated with it.
Currently WHO’s grant is pending, wherein Foreign Secretary Harsh Shringla will soon chair a conference with Bharat Biotech on Monday to accelerate the process. Bharat Biotech would provide the clinical data and clearance data in accordance with WHO guidelines for the same.
While addressing the members of the FICCI Ladies Organisation in Hyderabad, Dr. Raches Ella affirmed that the company is keen to boost up its capacity to 700 million doses by the end of 2021. On the other hand, paediatric trials for covaxin would begin from next month.